ANZGOG ASM 2021 Presentations
The following presentations from the ANZGOG Virtual ASM 2021 have been shared with consent.
-
Session 1: Wellbeing and Gynae-oncology Advanced Nursing Practice Workshop
- Stress and Self Care Leanne Wall
- Clinical Supervision Cath Adams
- Defining the Characteristics of Expert Cancer Nursing Mei Krishnasamy
- Gynae-oncology Advanced Practice Nursing Roles Olivia Cook
- Nurse Practitioner Role in Gynae-oncology Shannon Philp
-
Session 2: Pure Science Symposium
- Novel Ovarian Cancer Treatment Using CAR-T Cells Targeting the Non-functional P2X7 Receptor Carmela Ricciardelli
- The Role of USPP9X in Low-Grade Serous Ovarian Cancer Abhimanyu Nigam
- A Single Cell Approach to Tumour Cell Heterogeneity and Therapy Response in Ovarian Cancer Naisana Seyedasli
- The Challenges of Classifying Mucinous Ovarian Tumours for Research: An Ovarian Tumour Tissue Analysis Consortium Study Nicki Meagher
- The INOVATe Study: Real-time Tumour Profiling in Women with Ovarian Cancer Natalie Bouantoun
- Genomics and Organoids: Developing 3D-based Therapeutic Options for Mucinous Ovarian Cancer Carolina Salazar
- Large Scale Genetic Studies of Endometrial Cancer to Identify Novel Drug Targets Dylan Glubb
- Fibroblast Growth Factor Receptor (FGFR2c) Mesenchymal Isoform Expression is Associated with Progestin treatment Failure in Complex Atypical Hyperplasia and Well Differentiated Endometrial CancerA Unique Cohort of Uterine Leiomyosarcoma in the WEHI-Stafford Fox Rare Cancer Program Asmerom Sengal
- A Unique Cohort of Uterine Leiomyosarcoma in the WEHI-Stafford Fox Rare Cancer Program Genevieve Dall
- Novel Therapies to Target High-Grade Serous Ovarian Cancers (GCSOCs) Kum Kum Khanna
- Investigation of the Epigenome and Transcriptome of High-Grade Serous Ovarian Cancer After DNMT Inhibitor and Platinum Chemotherapy Treatment Michelle Brown
- Increased FOXJ1 Protein Expression is Associated With Improved Overall Survival in High-Grade Serous Ovarian Carcinoma an Ovarian Tumour Tissue Analysis Consortium Study Ashley Weir
- A Novel ROR2 Targeted Nanomedicine Inhibits the Metastatic Potential of High Grade Serous Ovarian Cancer Dongli Liu
- Targeting the RAS/MAPK Pathway in Low-Grade Serous and Mucinous Ovarian Cancer Cell Lines Ida Barner Madsen
-
Session 1: Keynote 1
-
Session 2: ANZGOG
- Consumer Research Panel Update Wanda Lawson
-
Session 3: Keynote 2- Cervix
-
Session 5: Oral Abstracts
- Maintenance Olaparib for Patients (Pts) with Newly Diagnosed, Advanced Ovarian Cancer (OC) and a BRCA Mutation (Brcam): 5-Year (Y) Follow-Up (f/u) from SOLO1 Michael Friedlander
- Inter- and Intra-Observer Variability of RECIST Assessment in Ovarian Cancer Michael Krasovitsky
- HPV independent Vulval Squamous Cell Carcinoma: is the poorer prognosis due to late presentation in an older population? Lois Eva
-
Session 6: Uterine Cancer
- Endometrial Cancer – Changing Role of Systemic Therapy Amit Oza
- The Evidence on Surgical Staging of Endometrial Cancer Andreas Obermair
- Adjuvant Therapy in Endometrial Cancer – Chemotherapy vs Radiation Michelle Vaughan
-
Session 7: PROs -From Research Into Practice
- The Journey Towards Incorporating Patient Reported Outcome Measures (PROMS) as Endpoints in Ovarian Cancer Clinical Trials – Are We There Yet? Michael Friedlander
- Getting the MOST Out of Pros in Clinic Madeleine King
- Implementing Psychosocial PROM in Routine Clinical Practice: Challenges and strategies Phyllis Butow
